Is XTL Biopharmaceutica Stock a Good Investment?
XTL Biopharmaceutica Investment Advice | XTLB |
- Examine XTL Biopharmaceutica's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research XTL Biopharmaceutica's leadership team and their track record. Good management can help XTL Biopharmaceutica navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact XTL Biopharmaceutica's business and its evolving consumer preferences.
- Compare XTL Biopharmaceutica's performance and market position to its competitors. Analyze how XTL Biopharmaceutica is positioned in terms of product offerings, innovation, and market share.
- Check if XTL Biopharmaceutica pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about XTL Biopharmaceutica's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in XTL Biopharmaceuticals Ltd stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if XTL Biopharmaceuticals Ltd is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine XTL Biopharmaceutica Stock
Researching XTL Biopharmaceutica's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The book value of the company was at this time reported as 0.01. The company recorded a loss per share of 0.03. XTL Biopharmaceuticals last dividend was issued on the 10th of February 2017. The entity had 1:5 split on the 10th of February 2017.
To determine if XTL Biopharmaceutica is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding XTL Biopharmaceutica's research are outlined below:
| XTL Biopharmaceutica generated a negative expected return over the last 90 days | |
| XTL Biopharmaceutica has high historical volatility and very poor performance | |
| XTL Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (1.78 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| XTL Biopharmaceuticals Ltd currently holds about 5.16 M in cash with (707 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.95. | |
| XTL Biopharmaceutica has a frail financial position based on the latest SEC disclosures | |
| Latest headline from prnewswire.com: TargED Biopharmaceuticals doses first participant in Phase 1 clinical trial of TGD001, a groundbreaking thrombolytic in acute ischemic stroke and TTP |
XTL Biopharmaceutica Quarterly Accounts Payable |
|
XTL Biopharmaceutica uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in XTL Biopharmaceuticals Ltd. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to XTL Biopharmaceutica's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know XTL Biopharmaceutica's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as XTL Biopharmaceutica is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading XTL Biopharmaceuticals Ltd backward and forwards among themselves. XTL Biopharmaceutica's institutional investor refers to the entity that pools money to purchase XTL Biopharmaceutica's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Noked Israel Ltd | 2024-09-30 | 198.9 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 26.5 K | Rhumbline Advisers | 2024-09-30 | 6.5 K | Bnp Paribas Arbitrage, Sa | 2024-06-30 | 0.0 | Ubs Group Ag | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 |
XTL Biopharmaceutica's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.24 M.Market Cap |
|
XTL Biopharmaceutica's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Capital Employed | (0.34) | (0.33) |
Determining XTL Biopharmaceutica's profitability involves analyzing its financial statements and using various financial metrics to determine if XTL Biopharmaceutica is a good buy. For example, gross profit margin measures XTL Biopharmaceutica's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of XTL Biopharmaceutica's profitability and make more informed investment decisions.
Please note, the presentation of XTL Biopharmaceutica's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, XTL Biopharmaceutica's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of XTL Biopharmaceutica's management manipulating its earnings.
Evaluate XTL Biopharmaceutica's management efficiency
XTL Biopharmaceuticals has return on total asset (ROA) of (0.1378) % which means that it has lost $0.1378 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1307) %, meaning that it created substantial loss on money invested by shareholders. XTL Biopharmaceutica's management efficiency ratios could be used to measure how well XTL Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities. As of December 26, 2024, Return On Tangible Assets is expected to decline to -0.0009. The current year's Return On Capital Employed is expected to grow to -0.33. At present, XTL Biopharmaceutica's Other Current Assets are projected to decrease significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 4.6 M, whereas Total Assets are forecasted to decline to about 2.3 M.| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (4.84) | (4.60) | |
| Price Book Value Ratio | 2.30 | 2.41 | |
| Enterprise Value Multiple | (4.84) | (4.60) | |
| Price Fair Value | 2.30 | 2.41 | |
| Enterprise Value | 3.7 M | 3.9 M |
The decision-making processes within XTL Biopharmaceutica are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Beta 0.996 |
Basic technical analysis of XTL Stock
As of the 26th of December, XTL Biopharmaceutica maintains the insignificant Risk Adjusted Performance, mean deviation of 4.7, and Standard Deviation of 7.53. In relation to fundamental indicators, the technical analysis model lets you check available technical drivers of XTL Biopharmaceuticals Ltd, as well as the relationship between them.XTL Biopharmaceutica's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific XTL Biopharmaceutica insiders, such as employees or executives, is commonly permitted as long as it does not rely on XTL Biopharmaceutica's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases XTL Biopharmaceutica insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
XTL Biopharmaceutica's Outstanding Corporate Bonds
XTL Biopharmaceutica issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. XTL Biopharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most XTL bonds can be classified according to their maturity, which is the date when XTL Biopharmaceuticals Ltd has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| XEL 46 01 JUN 32 Corp BondUS98388MAD92 | View | |
| XEL 235 15 NOV 31 Corp BondUS98388MAC10 | View | |
| XEL 175 15 MAR 27 Corp BondUS98388MAB37 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| XCEL ENERGY INC Corp BondUS98389BAU44 | View | |
| XCEL ENERGY INC Corp BondUS98389BAV27 | View | |
| XCEL ENERGY INC Corp BondUS98389BAR15 | View | |
| XCEL ENERGY INC Corp BondUS98389BAN01 | View |
Understand XTL Biopharmaceutica's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing XTL Biopharmaceutica's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.07) | |||
| Mean Deviation | 4.7 | |||
| Coefficient Of Variation | (7,087) | |||
| Standard Deviation | 7.53 | |||
| Variance | 56.74 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | (0.44) | |||
| Treynor Ratio | (0.08) | |||
| Maximum Drawdown | 45.84 | |||
| Value At Risk | (9.55) | |||
| Potential Upside | 9.6 | |||
| Skewness | 0.67 | |||
| Kurtosis | 4.54 |
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.07) | |||
| Mean Deviation | 4.7 | |||
| Coefficient Of Variation | (7,087) | |||
| Standard Deviation | 7.53 | |||
| Variance | 56.74 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | (0.44) | |||
| Treynor Ratio | (0.08) | |||
| Maximum Drawdown | 45.84 | |||
| Value At Risk | (9.55) | |||
| Potential Upside | 9.6 | |||
| Skewness | 0.67 | |||
| Kurtosis | 4.54 |
Consider XTL Biopharmaceutica's intraday indicators
XTL Biopharmaceutica intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of XTL Biopharmaceutica stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 7677.45 | |||
| Daily Balance Of Power | 0.5789 | |||
| Rate Of Daily Change | 1.12 | |||
| Day Median Price | 1.91 | |||
| Day Typical Price | 1.97 | |||
| Price Action Indicator | 0.3 | |||
| Period Momentum Indicator | 0.22 |
XTL Stock media impact
Far too much social signal, news, headlines, and media speculation about XTL Biopharmaceutica that are available to investors today. That information is available publicly through XTL media outlets and privately through word of mouth or via XTL internal channels. However, regardless of the origin, that massive amount of XTL data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of XTL Biopharmaceutica news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of XTL Biopharmaceutica relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to XTL Biopharmaceutica's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive XTL Biopharmaceutica alpha.
XTL Biopharmaceutica Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards XTL Biopharmaceutica can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
XTL Biopharmaceutica Corporate Management
| Itay CPA | Chief Officer | Profile | |
| Itay Weinstein | Chief Officer | Profile | |
| Shlomo Shalev | CEO Director | Profile | |
| Ronen Kantor | Company Sec | Profile |
Already Invested in XTL Biopharmaceuticals Ltd?
The danger of trading XTL Biopharmaceuticals Ltd is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of XTL Biopharmaceutica is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than XTL Biopharmaceutica. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile XTL Biopharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XTL Biopharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share (0.03) | Return On Assets (0.14) | Return On Equity (0.13) |
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between XTL Biopharmaceutica's value and its price, as these two are different measures arrived at by various means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.